telavancin and Acute-Kidney-Injury

telavancin has been researched along with Acute-Kidney-Injury* in 3 studies

Trials

1 trial(s) available for telavancin and Acute-Kidney-Injury

ArticleYear
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Gram-positive bacterial infections are an important cause of morbidity and death among cancer patients, despite current therapy. In this case-control study, we evaluated the clinical outcomes and safety of telavancin in cancer patients with uncomplicated Gram-positive bloodstream infections (BSIs). Between March 2011 and May 2013, we enrolled cancer patients with uncomplicated Gram-positive BSIs to receive intravenous telavancin therapy for at least 14 days for Staphylococcus aureus and 7 days for other Gram-positive cocci. Patients with baseline creatinine clearance (CLCR) values of >50 ml/min received 10 mg/kg/day of telavancin, and those with CLCR values between 30 and 49 ml/min received 7.5 mg/kg/day. Patients were compared with a retrospective cohort of 39 historical patients with Gram-positive BSIs, matched for underlying malignancy, infecting organism, and neutropenia status, who had been treated with vancomycin. A total of 78 patients were analyzed, with 39 in each group. The most common pathogen causing BSIs was S. aureus (51%), followed by alpha-hemolytic streptococci (23%), Enterococcus spp. (15%), coagulase-negative staphylococci (8%), and beta-hemolytic streptococci (3%). Sixty-two percent of patients had hematological malignancies, and 38% had solid tumors; 51% of the patients were neutropenic. The overall response rate determined by clinical outcome and microbiological eradication at 72 h following the initiation of therapy, in the absence of relapse, deep-seated infections, and/or infection-related death, was better with telavancin than with vancomycin (86% versus 61%; P = 0.013). Rates of drug-related adverse events were similar in the two groups (telavancin, 31%; vancomycin, 23%; P = 0.79), with similar rates of renal adverse events. Telavancin may provide a useful alternative to standard vancomycin therapy for Gram-positive BSIs in cancer patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT01321879.).

    Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hematologic Neoplasms; Humans; Lipoglycopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Neutropenia; Pilot Projects; Recurrence; Treatment Outcome; Vancomycin

2016

Other Studies

2 other study(ies) available for telavancin and Acute-Kidney-Injury

ArticleYear
Telavancin-associated acute kidney injury
.
    Clinical nephrology, 2019, Volume: 91, Issue:3

    Telavancin is a lipoglycopeptide semi-synthetic derivative of vancomycin used for select infections caused by Gram-positive bacteria including

    Topics: Acute Kidney Injury; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Nephritis, Interstitial; Staphylococcal Infections

2019
Acute renal insufficiency during telavancin therapy in clinical practice.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:3

    To describe the tolerance to long-term telavancin therapy among inpatients as it relates to nephrotoxicity.. Retrospective cohort study of adult patients who received telavancin at the Barnes-Jewish Hospital from 1 September 2009 to 1 December 2010. Patients who received less than three doses of telavancin, were on haemodialysis prior to telavancin administration or died within 48 h of initial telavancin administration were excluded.. Twenty-one patients received telavancin and met the inclusion criteria. Seven of 21 patients (33%) developed acute renal insufficiency during therapy. Patients who developed acute renal insufficiency had a mean glomerular filtration rate reduction of 56 mL/min/1.73 m(2). In the univariate analysis, high body mass index (P=0.025), use of intravenous contrast dye (P=0.017) and prior serum vancomycin trough levels >20 mg/L (P=0.017) were associated with developing acute renal insufficiency. Two patients required haemodialysis; two had persistent renal insufficiency.. Supratherapeutic vancomycin trough levels, high body mass index and receipt of intravenous contrast dye prior to telavancin therapy were associated with acute renal insufficiency.

    Topics: Acute Kidney Injury; Adult; Aged; Aminoglycosides; Anti-Infective Agents; Cohort Studies; Female; Humans; Lipoglycopeptides; Male; Middle Aged; Retrospective Studies; Risk Factors; Staphylococcal Infections; Survival Analysis

2012